Novel Nanolipoidal Systems for the Management of Skin Cancer

Skin Cancer
18/08/2020

Recent Pat Drug Deliv Formul. 2020 Aug 17. doi: 10.2174/1872211314666200817115700. Online ahead of print.

ABSTRACT

Skin cancer, among the various kinds of cancer, is a type that emerges from skin due to the incident growth of abnormal cells. These cells are capable of spreading and invading the other parts of body. The occurrence of non-melanoma and melanoma, which are the major types of skin cancer, has increased over the past decades. Exposure to ul-traviolet radiations (UV) is the main associative cause of skin cancer. UV exposure can inactivate tumor suppressor genes while activating various oncogenes.


The conventional techniques like surgical removal, chemotherapy and radiation ther-apy lack the potential for targeting cancer cells and harm the normal cells. However, the novel therapeutics show promis-ing improvements in effectiveness of treatment, survival rates and better quality of life for patients. Different methodolo-gies are involved in the skin cancer therapeutics for delivering the active ingredients to the target sites. Nano carriers are very efficient as they have the ability to improve the stability of drugs and further enhance their penetration into the tumor cells. The recent developments and research in nanotechnology have entitled several targeting and therapeutic agents to be incorporated into nanoparticles for an enhancive treatment of skin cancer. To protect the research works in the field of nanolipoidal systems various patents have been introduced. Some of the patents acknowledge responsive liposomes for specific targeting, nanocarriers for the delivery or co-delivery of chemotherapeutics, nucleic acids as well as photosensi-tizers. Further recent patents on the novel delivery systems have also been included here.